German biotech CureVac B.V., which is in early stages of testing its coronavirus vaccine, said on Monday it expects to raise up to $213 million in its U.S. initial public offering (IPO). CureVac said it expects its offering of 13.33 million shares to be priced between $14.00 and $16.00 per share.
